Human medicines European public assessment report (EPAR): Ivabradine Zentiva, ivabradine, Date of authorisation: 11/11/2016, Revision: 7, Status: Authorised

Submitted by Anonymous (not verified) on 17 July 2025 - 13:39

Human medicines European public assessment report (EPAR): Ivabradine Zentiva, ivabradine, Date of authorisation: 11/11/2016, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Coagadex, human coagulation factor X, Date of authorisation: 16/03/2016, Revision: 11, Status: Authorised

Submitted by Anonymous (not verified) on 17 July 2025 - 13:21

Human medicines European public assessment report (EPAR): Coagadex, human coagulation factor X, Date of authorisation: 16/03/2016, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR): Byooviz, ranibizumab, Date of authorisation: 18/08/2021, Revision: 10, Status: Authorised

Submitted by Anonymous (not verified) on 17 July 2025 - 12:54

Human medicines European public assessment report (EPAR): Byooviz, ranibizumab, Date of authorisation: 18/08/2021, Revision: 10, Status: Authorised

Human medicines European public assessment report (EPAR): Fymskina, ustekinumab, Date of authorisation: 25/09/2024, Revision: 4, Status: Authorised

Submitted by Anonymous (not verified) on 17 July 2025 - 11:15

Human medicines European public assessment report (EPAR): Fymskina, ustekinumab, Date of authorisation: 25/09/2024, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Mepact, mifamurtide, Date of authorisation: 06/03/2009, Revision: 21, Status: Authorised

Submitted by Anonymous (not verified) on 17 July 2025 - 10:53

Human medicines European public assessment report (EPAR): Mepact, mifamurtide, Date of authorisation: 06/03/2009, Revision: 21, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More